Lingyan Jin
Cardiology researcher in Qiangsun Zheng's group in Xi'an who studies how metabolism and aging make the heart's upper chambers prone to atrial fibrillation
Department of Cardiology, The Second Affiliated Hospital of Xi'an Jiaotong University (papers 2023–2026)
Lingyan Jin is first author of the Atlas study JIN2026B on rapamycin and atrial fibrillation, the most common lasting heart rhythm disorder. Its risk climbs steeply with age. To mimic aging, the team injected mice with D-galactose, a sugar that speeds up age-like damage. Rapamycin in the food lowered how easily the aged mice could be pushed into atrial fibrillation, and it eased the structural and electrical changes in the atria, the heart's upper chambers. Mitochondria worked better and the animals responded better to insulin.
The unusual part is the mechanism. Rapamycin is known as an mTOR blocker, but here the protective effect ran mainly through lower activity of HIF-1 alpha, a protein that reshapes cell metabolism when oxygen is short, and the authors describe it as independent of mTOR. This is one mouse model of accelerated aging, so it is a lead for heart rhythm research rather than evidence for treating people.
Jin's other papers come from the same Xi'an group, led by cardiologist Qiangsun Zheng with Xinghua Qin of Northwestern Polytechnical University. They treat atrial fibrillation partly as a metabolic disease: an exercise-released molecule, BAIBA, protected obese mice (2024); the metabolite succinate made mice more prone to the arrhythmia (2025); branched-chain amino acids raised the risk while swimming exercise lowered it (2025); and very hard exercise raised the risk through excess autophagy (2025). Jin also co-authored a 2024 review on how energy metabolism and the electrical activity of the atria are coupled.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | A | Rapamycin attenuates age-related atrial remodeling and fibrillation by targeting HIF-1α-mediated metabolic dysregulation. JIN2026B First author: in D-galactose-aged mice, dietary rapamycin reduced atrial fibrillation susceptibility and atrial remodelling, mainly through lower HIF-1 alpha activity rather than mTOR. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Lingyan Jin.
ShowHide
- Qiangsun Zheng Cardiologist at the Second Affiliated Hospital of Xi'an Jiaotong University whose group studies atrial fibrillation as a disorder of heart metabolism, in mice and in patients
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.